Joined September 2020
- Tweets 653
- Following 483
- Followers 1,341
- Likes 1,430
367 Photos and videos
Chimeric CAR T therapy delivers durable disease control in early GI cancer trial | $CHM Media coverage by @AusBiotech
biotechdispatch.com.au/news/… l
1
8
162
We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease. $CHM CDH17 expanded & persisted in all treated patients, with evidence of disease control in heavily pre-treated metastatic cancer patients.
app.sharelinktechnologies.co…
1
9
201
We’re in Philadelphia visiting Minaris for a closer look at a manufacturing run for $CHM CDH17. CEO Dr Rebecca McQualter and Head of Manufacturing Dr Agathe Bourgogne visited the site as CHM CDH17 progresses through Phase 1/2 clinical development in gastrointestinal cancers.
1
8
259
“We’re just about to hit a very big inflection point.”
From our CEO Dr Rebecca McQualter, speaking with @wholesaleinvest.
🎥 Watch the $CHM interview below.
youtu.be/Nkg4zaS36Sk?si=_NCx…
#CellTherapy #Oncology #Biotech #ASX #Chimeric
6
230
Our Quarterly Activities Report for the period ending 31 March 2026 has been released.
View the full $CHM report: app.sharelinktechnologies.co…
3
120
Top 10 at 11: Chimeric has complete response in 60pc of leukemia cohort | $CHM Medica coverage by @StockheadAU.
stockhead.com.au/news/top-10…
4
129
We’ve achieved 60% CR/CRi in the ADVENT-AML NCT05834244 Phase 1B clinical trial, with 25 patients enrolled, 60% have demonstrated complete responses. High risk, frontline patients are being treated with CHM CORE-NK standard of care.
app.sharelinktechnologies.co…
$CHM #Biotech
1
3
5
266
From CEO Dr Rebecca McQualter at the NWR Healthcare Conference: A $CHM CDH17 patient has reached 15 months with no new tumours, maintaining chemotherapy-free progression-free survival. CHM CDH17 has now advanced to Dose Level 3.
🎥 Watch the full replay:
youtube.com/watch?v=CxOg6sU7…
1
4
164
The replay of our CEO, Dr Rebecca McQualter’s presentation from today’s NWR Virtual Healthcare Conference is now available.
Watch the full replay here: youtube.com/watch?v=CxOg6sU7…
#ChimericTherapeutics #CHM #HealthcareConference #Biotech #InvestorUpdate #Fibrosis #ASX @NWRcomms
3
134
Our CEO Dr Rebecca McQualter presented at the @NWRcomms Virtual Healthcare Conference today.
View the full presentation: app.sharelinktechnologies.co…
#ChimericTherapeutics $CHM #HealthcareConference #Biotech #InvestorUpdate #Webinar #Fibrosis #MedicalResearch #ASX
3
78
REMINDER | CEO Dr. Rebecca McQualter will present tomorrow at 10:00 am AEDT (25 March) at the
@NWRcomms Healthcare Conference.
📌 Register here: us02web.zoom.us/webinar/regi…
Questions can be submitted to: matt@nwrcommunications.com.au.
More info: nwrcommunications.com/events…
$CHM
2
69
CEO Dr. Rebecca McQualter will present at 10:00am AEDT on 25 March 2026 at the @NWRcomms Healthcare Conference.
📌 Register here: us02web.zoom.us/webinar/regi…
Questions can be submitted live or in advance via matt@nwrcommunications.com.au.
More info: nwrcommunications.com/events…
$CHM
4
139
Letter to Shareholders: March 2026
View the full $CHM Announcement here: app.sharelinktechnologies.co…
5
98
In case you missed it: @Chimeric was featured in @StockheadAU's #Health & #Biotech Investor Guide 2026.
The segment highlights our lead CAR-T therapy $CHM CDH17, early patient outcomes from our US Phase 1/2 trial, and our focus on tackling solid tumours.
Watch the feature below.
5
127
March is Colorectal Cancer Awareness Month. $CHM CDH17 is being studied in advanced colorectal cancer and other gastrointestinal cancers in our Phase 1/2 trial. Our focus is progressing CHM CDH17 through clinical development advancing new potential treatment options for patients.
4
91
We’ve received $1,785,000 from Radium Capital under a funding facility secured against our anticipated FY26 Research and Development Tax Incentive. Funds will support our clinical trial pipeline and general working capital.
app.sharelinktechnologies.co…
$CHM #CellTherapy
1
4
183
We've released our Half-year Report ended 31 December 2025.
View the full $CHM report here: app.sharelinktechnologies.co…
3
77
We’ve entered into an arrangement to return CHM CLTX to City of Hope. Following a strategic review, the Board determined this represents a disciplined capital management decision aligned with our focus on advancing $CHM CDH17.
app.sharelinktechnologies.co…
5
110
We’re featured in the latest @StockheadAU Investor Guide, highlighting the progress of our US clinical programs and the patient impact driving our work.
Read more in the latest Stockhead Investor Guide: stockhead.com.au/investor-gu…
$CHM
2
80